WILMINGTON, Del.— Accolade Pharmaceuticals LLC announced today the signing of a global licensing agreement with Australian life sciences company, Invion Limited, for the development and commercialization of inhaled formulations for the asthma treatment drug, zafirlukast. This exclusive license grants Invion rights to apply the drug in creating inhaled treatments for asthma as well as other respiratory conditions. As a leukotriene receptor antagonist (LTRA), also known as an anti-leukotriene, zafirlukast works to reduce inflammation, airway constriction, and mucus buildup in the lungs by blocking the action of leukotrienes; chemicals that are part of the immune system’s inflammatory response.
Currently marketed as Accolate® by AstraZeneca in the United States, zafirlukast is solely available in oral formulation and is indicated for the prophylaxis and chronic treatment of asthma “We are excited to partner our inhaled program with Invion. This is a very seasoned management team with a strong track-record of drug development.” says John Mohr, Co-Founder and Chief Executive Officer of Accolade Pharmaceuticals.
“The development of inhaled zafirlukast will utilize existing knowledge, skills and competencies in the Invion clinical team, while strengthening Invion’s development pipeline and asset commercialization opportunities,” said Invion Chief Executive Officer, Dr. Greg Collier in a press release made available on their company website. INV104, as the product is to be known, will be one of three Invion products that are currently in phase II clinical trials in the United States.
About Accolade Pharmaceuticals LLC
Accolade is a private, specialty biopharmaceutical company that focuses on the development of known drug products for the treatment of allergic diseases. Founded in 2012, Accolade is quickly advancing a pipeline of products for treating multitude allergic conditions, including allergic rhinitis, conjunctivitis and skin disorders. For more information about Accolade Pharmaceuticals LLC, please visit: www.accoladepharma.com.